Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 3/20 | 0.42 |
| ▸ | KCNK3 | O14649 | 7/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19110810 | 0.95 | ENPP2 (0.40) | ENPP2KCNK3ALDH1A1IDO1TDO2 | |
| SCHEMBL19110822 | 0.90 | ENPP2 (0.49) | ENPP2KCNK3LMNASIGMAR1 | |
| SCHEMBL19110820 | 0.90 | SMN1; SMN2 (0.47) | ALDH1A1TP53KDM4ESMN1; SMN2 | |
| SCHEMBL17317608 | 0.89 | ENPP2 (0.44) | ENPP2KCNK3TP53SMN1; SMN2CACNA1G | |
| SCHEMBL19110816 | 0.88 | KCNK3 (0.44) | ENPP2KCNK3ALDH1A1LMNAKDM4E | |
| SCHEMBL19110843 | 0.88 | ENPP2 (0.48) | ENPP2KCNK3LMNASMN1; SMN2SIGMAR1 | |
| SCHEMBL19110626 | 0.88 | KCNK3 (0.41) | KCNK3ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL19110835 | 0.87 | ENPP2 (0.48) | ENPP2KCNK3LMNA | |
| SCHEMBL19110817 | 0.86 | KCNK3 (0.44) | ENPP2KCNK3LMNASIGMAR1 | |
| SCHEMBL19110839 | 0.85 | KCNK3 (0.45) | ENPP2KCNK3ALDH1A1KDM4EPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170197960-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197960-A1 | ATX MODULATING AGENTS | ENPP2, ATXN10, ATXN2 | ENPP2 1/4885KCNK3 1825/4885ALDH1A1 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.